Singaporean sovereign wealth fund leads investment in ‘digital twin’ company targeting chronic metabolic disease.
Silicon Valley-based health tech firm Twin Health has secured $50 million in funding to advance its technology aimed at reversing, improving, and preventing chronic metabolic diseases. Interestingly, the funding round was led by Singapore’s state-owned investment firm Temasek, with participation from existing investors ICONIQ Growth, Sofina, Peak XV, and Helena. Singapore is widely hailed for its approach to longevity – it already has one of the highest life expectancy rates in the world, and is considered by many to be the 6th Blue Zone.
Chronic metabolic diseases, affecting approximately 60% of Americans, pose a global health challenge, contributing to a rise in conditions like type 2 diabetes, obesity, fatty liver, and dyslipidemia. Twin Health’s “Whole Body Digital Twin” technology uses artificial intelligence to create dynamic models of individual metabolisms, leveraging data collected via wearable sensors, clinical lab parameters, and self-reported preferences. A mobile app provides personalized guidance in areas such as nutrition, sleep, activity and stress, delivered in collaboration with a clinical care team.
“Today, a large and growing number of people around the world are suffering from chronic metabolic disease including type-2 diabetes, pre-diabetes, and obesity,” said Kevin Johnson, former CEO of Starbucks, who sits on Twin Health’s board of directors. “Twin’s innovative approach combines advanced technology, machine learning, and compassionate care to change the lives of these people. It allows people to take control of their health and reverse these metabolic diseases, including type-2 diabetes, while also eliminating the need for high-cost medications.”
Twin Health claims it has completed the “world’s first” randomized controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology.
The results of the one-year RCT, recently published in the American Association of Clinical Endocrinology, demonstrated a 2.9% reduction in HbA1c in the intervention group, along with a significant elimination (94%) of type 2 diabetes medications. Participants also experienced an average weight loss of 16.3 lbs, and 64% witnessed a normalization of baseline non-alcoholic fatty liver disease. The company says that the RCT is now entering its third year, and is showing “sustained health outcomes.”
“The funding will help propel our strategy to scale the availability of our transformative technology and the way it’s deployed to even more health plans and employer partners, achieving lower costs, better outcomes and higher satisfaction among their members and employees,” said Jahangir Mohammed, CEO of Twin Health.